122 related articles for article (PubMed ID: 37230023)
1. GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells.
Zhu Z; Shen H; Xu J; Fang Z; Wo G; Ma Y; Yang K; Wang Y; Yu Q; Tang JH
Drug Resist Updat; 2023 Jul; 69():100974. PubMed ID: 37230023
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA lnc-LOC645166 promotes adriamycin resistance via NF-κB/GATA3 axis in breast cancer.
Zheng R; Jia J; Guan L; Yuan H; Liu K; Liu C; Ye W; Liao Y; Lin S; Huang O
Aging (Albany NY); 2020 May; 12(10):8893-8912. PubMed ID: 32461377
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
4. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.
Kim B; Stephen SL; Hanby AM; Horgan K; Perry SL; Richardson J; Roundhill EA; Valleley EM; Verghese ET; Williams BJ; Thorne JL; Hughes TA
BMC Cancer; 2015 Sep; 15():634. PubMed ID: 26362310
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
Contreras-Espinosa L; Alcaraz N; De La Rosa-Velázquez IA; Díaz-Chávez J; Cabrera-Galeana P; Rebollar-Vega R; Reynoso-Noverón N; Maldonado-Martínez HA; González-Barrios R; Montiel-Manríquez R; Bautista-Sánchez D; Castro-Hernández C; Alvarez-Gomez RM; Jiménez-Trejo F; Tapia-Rodríguez M; García-Gordillo JA; Pérez-Rosas A; Bargallo-Rocha E; Arriaga-Canon C; Herrera LA
J Mol Diagn; 2021 Oct; 23(10):1306-1323. PubMed ID: 34358678
[TBL] [Abstract][Full Text] [Related]
7. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.
Cohen H; Ben-Hamo R; Gidoni M; Yitzhaki I; Kozol R; Zilberberg A; Efroni S
Breast Cancer Res; 2014 Nov; 16(6):464. PubMed ID: 25410484
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer.
Aguiari G; Crudele F; Taccioli C; Minotti L; Corrà F; Keillor JW; Grassilli S; Cervellati C; Volinia S; Bergamini CM; Bianchi N
Int J Biol Sci; 2022; 18(1):1-14. PubMed ID: 34975314
[TBL] [Abstract][Full Text] [Related]
9. C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.
Ma J; Liu C; Yang D; Song J; Zhang J; Wang T; Wang M; Xu W; Li X; Ding S; Zhan J; Zhang H
Sci China Life Sci; 2019 Sep; 62(9):1229-1242. PubMed ID: 31376015
[TBL] [Abstract][Full Text] [Related]
10. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
11. GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.
Chu IM; Michalowski AM; Hoenerhoff M; Szauter KM; Luger D; Sato M; Flanders K; Oshima A; Csiszar K; Green JE
Oncogene; 2012 Apr; 31(16):2017-27. PubMed ID: 21892208
[TBL] [Abstract][Full Text] [Related]
12. GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion.
Sun J; He H; Pillai S; Xiong Y; Challa S; Xu L; Chellappan S; Yang S
J Biol Chem; 2013 Dec; 288(52):36971-82. PubMed ID: 24235142
[TBL] [Abstract][Full Text] [Related]
13. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
14. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.
Sereesongsaeng N; McDowell SH; Burrows JF; Scott CJ; Burden RE
Breast Cancer Res; 2020 Dec; 22(1):139. PubMed ID: 33298139
[TBL] [Abstract][Full Text] [Related]
16. GATA3 recruits UTX for gene transcriptional activation to suppress metastasis of breast cancer.
Yu W; Huang W; Yang Y; Qiu R; Zeng Y; Hou Y; Sun G; Shi H; Leng S; Feng D; Chen Y; Wang S; Teng X; Yu H; Wang Y
Cell Death Dis; 2019 Nov; 10(11):832. PubMed ID: 31685800
[TBL] [Abstract][Full Text] [Related]
17. Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß.
Chu IM; Lai WC; Aprelikova O; El Touny LH; Kouros-Mehr H; Green JE
PLoS One; 2013; 8(4):e61125. PubMed ID: 23577196
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
19. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.
Larsen V; Barlow WE; Yang JJ; Zhu Q; Liu S; Kwan ML; Ergas IJ; Roh JM; Hutchins LF; Kadlubar SA; Albain KS; Rae JM; Yeh IT; Ravdin PM; Martino S; Lyss AP; Osborne CK; Hortobagyi GN; Kushi LH; Hayes DF; Ambrosone CB; Yao S
Clin Breast Cancer; 2019 Aug; 19(4):225-235.e2. PubMed ID: 30928413
[TBL] [Abstract][Full Text] [Related]
20. Etoposide in combination with erastin synergistically altered iron homeostasis and induced ferroptotic cell death through regulating IREB2/FPN1 expression in estrogen receptor positive-breast cancer cells.
Ozkan E; Bakar-Ates F
Life Sci; 2023 Jan; 312():121222. PubMed ID: 36442526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
